Robert A. Wolff

46.0k citations

462 papers · 28.9k indexed · 8 hit papers · h-index 81

Impact in

Oncology top 0.01%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
Cancer Research top 0.05%
- Cancer Genomics and Diagnostics

Papers in

Oncology 358
- Pancreatic and Hepatic Oncology Research 229
- Colorectal Cancer Treatments and Studies 96
Cancer Research 144
- Cancer Genomics and Diagnostics 116

Co-authors: James L. Abbruzzese Christopher H. Crane Douglas B. Evans Peter W. T. Pisters Jeffrey E. Lee Gauri R. Varadhachary Donghui Li Jean‐Nicolas Vauthey
Journals: Journal of Clinical Oncology (150 papers)Cancer (24 papers)International Journal of Radiation Oncology*Biology*Physics (22 papers)Annals of Surgical Oncology (20 papers)Oncotarget (11 papers)
Partner nations: United States Egypt Canada

In The Last Decade

Robert A. Wolff

449 papers receiving 28.4k citations

Hit Papers

8 papers align trajectories log scale

A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group 2020 · 468 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 The Oncologist
2019 JAMA Oncology
2008 Clinical Cancer Research
2008 Journal of Clinical Oncology
2008 Journal of the American College of Surgeons
2007 Journal of Clinical Oncology
2006 Annals of Surgical Oncology
2004 The Lancet

Peers

Countries citing papers authored by Robert A. Wolff

Since Specialization

Citations

This map shows the geographic impact of Robert A. Wolff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Wolff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Wolff more than expected).

Fields of papers citing papers by Robert A. Wolff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Wolff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Wolff. The network helps show where Robert A. Wolff may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Robert A. Wolff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert A. Wolff Line = papers co-authored together Robert A. Wolff links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Mutational and co-mutational landscape of early onset colorectal cancer Biomarkers ·TT Koca, M. S., Dong Linx, Aurora Mihaela Nedelcu, Michael G. White, John Paul Shen, Eduardo Vilar, Christine M. Parseghian, ZHAO Guo-shuai, Van K. Morris, Ryan Huey, Michael J. Overman, Robert A. Wolff, Kanwal Raghav, Jason Willis, Clauer Norbert, Andy Futreal, Y. Nancy You, Scott Kopetz	2025	6
2	Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer Annals of Surgery ·Gustavo Rostirolla, Ching‐Wei D. Tzeng, Laura R. Prakash, Jessica Maxwell, Rebecca A. Snyder, Michael P. Kim, Ryan Huey, Brandon G. Smaglo, Shubham Pant, Eugene J. Koay, Robert A. Wolff, Jeffery E. Lee, Matthew H. G. Katz, Naruhiko Ikoma	2024	3
3	Molecular and clinical features of pancreatic acinar cell carcinoma: A single institutional experience. Journal of Clinical Oncology ·F.J. Kuiper, Fengze Zhong, Abdelrahman Yousef, Mark W. Hurd, Huamin Wang, Anirban Maitra, Jason Willis, John Paul Shen, Shubham Pant, Brandon G. Smaglo, Robert A. Wolff, Dan Zhao	2024	0
4	1631P Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC) Annals of Oncology ·Zaid Memon, J. Salan, N. A. Tsalikova, Matthew H. G. Katz, Naruhiko Ikoma, 芳夫滝沢, Michael J. Overman, Shubham Pant, Christine Y. Wang, Robert A. Wolff, Milind Javle, Cullen M. Taniguchi, Ethan B. Ludmir, Prajnan Das, Albert C. Koong, Omar I. Vivar, S. Liu, Eric P. Tamm, Manoop S. Bhutani, Eugene J. Koay	2023	2
5	Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of the Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential Cancer Discovery ·Marta Sans, Yuki Makino, Jimin Min, Kimal Rajapakshe, Michele Yip-Schneider, C. Max Schmidt, Mark W. Hurd, Jared K. Burks, Javier A. Gomez, Fredrik I. Thege, Johannes F. Fahrmann, Robert A. Wolff, Michael P. Kim, Paola A. Guerrero, Anirban Maitra	2023	27
6	Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination Cancer Research Communications ·Adriane Moskalewicz, Jane V. Thomas, Kaysia Ludford, Jason Willis, Ida Yati, Kanwal Raghav, Benny Johnson, Arvind Dasari, Bryan K. Kee, Christine M. Parseghian, Michael S. Lee, D Munnisteri, Maria Pia Morelli, John Paul Shen, 成臣蝶野, Eduardo Vilar, Robert A. Wolff, Scott Kopetz, Michael J. Overman, Van K. Morris	2023	4
7	Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma The Oncologist ·Érico Castro, 朱旒琴, Mohammad A. Zeineddine, Abdelrahman Yousef, 成臣蝶野, Dr. D. Chandra Vadhana, Robert A. Wolff, Michael J. Overman, John Paul Shen	2023	1
8	Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy Clinical Cancer Research ·Sunyoung Lee, Rachna T. Shroff, Shalini Makawita, Lianchun Xiao, Lawrence Galuppo, Priya Bhosale, Soichiro Okura, Ahmed Shalaby, Kanwal Raghav, Shubham Pant, Robert A. Wolff, Milind Javle	2022	19
9	Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience The Oncologist ·Ida Yati, Jane E. Rogers, Hyunsoo Hwang, Wei Qiao, Lianchun Xiao, Arvind Dasari, Arya Samodra Hening, Van K. Morris, Robert A. Wolff, Kanwal Raghav, Ryan Huey, Christine M. Parseghian, Jason Willis, Scott Kopetz, Michael J. Overman, Benny Johnson	2022	14
10	PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer BMC Cancer ·Dolors Montlo, Suyu Liu, Junsheng Ma, Robert A. Wolff, Shubham Pant, Anirban Maitra, Eric P. Tamm, Priya Bhosale, Matthew H. G. Katz, Gauri R. Varadhachary, Eugene J. Koay	2022	7
11	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer Clinical Cancer Research ·Jennifer B. Goldstein, Li Zhao, Xuemei Wang, Alexandre Dupont, Michael J. Overman, Milind Javle, Rachna T. Shroff, Gauri R. Varadhachary, Robert A. Wolff, Florencia McAllister, P. Andrew Futreal, David R. Fogelman	2019	29
12	Underreporting of Research Biopsies from Clinical Trials in Oncology Clinical Cancer Research ·Christine M. Parseghian, Kanwal Raghav, Robert A. Wolff, Joe Ensor, James C. Yao, Lee M. Ellis, Alda L. Tam, Michael J. Overman	2017	14
13	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer Clinical Cancer Research ·Christine M. Parseghian, Nila U. Parikh, Ji Yuan Wu, Zhi-Qin Jiang, Laura E. Henderson, Feng Tian, Brice Pastor, Marc Ychou, Kanwal Raghav, Arvind Dasari, David R. Fogelman, Αναστασία Κατσιαμπούρα, David G. Menter, Robert A. Wolff, Cathy Eng, Michael J. Overman, Alain R. Thierry, Gary E. Gallick, Scott Kopetz	2017	47
14	A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients Supportive Care in Cancer ·David R. Fogelman, Jeffrey S. Morris, Lianchun Xiao, Moustapha Hassan, Carlo Smuraglia, Michael J. Overman, Masoud Haasan, Rachna T. Shroff, Gauri R. Varadhachary, Robert A. Wolff, Luis M. Vence, Anirban Maitra, Charles S. Cleeland, E. BUNCEL	2017	24
15	The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy Histopathology ·Laurice K. Fischer, Matthew H. G. Katz, 悦子井ノ口, Li Liu, Hua Wang, (unknown), Gauri R. Varadhachary, Robert A. Wolff, Jeffrey E. Lee, Anirban Maitra, Christina L. Roland, Jason B. Fleming, Jeannelyn S. Estrella, Asif Rashid, (unknown), (unknown)	2015	44
16	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations Molecular Cancer Therapeutics ·Prasanth Ganesan, Filip Jankú, Aung Naing, David S. Hong, Apostolia M. Tsimberidou, Gerald S. Falchook, Jennifer J. Wheler, Sarina A. Piha‐Paul, Siqing Fu, Vanda M. Stepanek, J. Jack Lee, Rajyalakshmi Luthra, Michael J. Overman, Scott Kopetz, Robert A. Wolff, Razelle Kurzrock	2013	38
17	PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors Clinical Cancer Research ·Funda Meric‐Bernstam, Argun Akçakanat, Huiqin Chen, Kim‐Anh Do, Takafumi Sangai, Farrell Adkins, Ana M. González-Angulo, Asif Rashid, Katherine Crosby, Mei Dong, Alexandria T. Phan, Robert A. Wolff, Sanjay Gupta, Gordon B. Mills, James C. Yao	2012	171
18	Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement Annals of Surgical Oncology ·Ross A. Abrams, Andrew M. Lowy, Eileen M. O’Reilly, Robert A. Wolff, Vincent J. Picozzi, Peter W. T. Pisters	2009	196
19	RhuMab VEGF (bevacizumab) with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer: An active, well tolerated regimen International Journal of Radiation OncologyBiologyPhysics ·Christopher H. Crane, Lee M. Ellis, M. OʼReilly, Linus Ho, James L. Abbruzzese, Misuzu Ishii, Chaan S. Ng, Chusilp Charnsangavej, Eric P. Tamm, Henry Q. Xiong, Marc E. Delclos, Robert A. Wolff	2004	3
20	Background and H2O2-induced micronuclei in peripheral blood lymphocytes as a risk factor for pancreatic cancer Cancer Research ·Ping Chang, Manal M. Hassan, James L. Abbruzzese, Douglas B. Evans, Robert A. Wolff, Renato Lenzi, Peter W. T. Pisters, Ajay K. Nooka, Donghui Li	2004	3

About Robert A. Wolff

Robert A. Wolff is a scholar working on Oncology, Cancer Research, Gastroenterology, Pulmonary and Respiratory Medicine and Hepatology, having authored 462 papers that have together received 28.9k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (229 papers), Cancer Genomics and Diagnostics (116 papers), Colorectal Cancer Treatments and Studies (96 papers), Neuroendocrine Tumor Research Advances (67 papers), Renal cell carcinoma treatment (51 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (50 papers), Gastric Cancer Management and Outcomes (49 papers) and Colorectal and Anal Carcinomas (44 papers). The work is most often cited by research in Oncology (21.7k citations), Cancer Research (6.2k citations), Pulmonary and Respiratory Medicine (8.4k citations), Hepatology (1.9k citations) and Gastroenterology (1.3k citations). Robert A. Wolff has collaborated with scholars based in United States, Egypt and Canada. Frequent co-authors include James L. Abbruzzese, Christopher H. Crane, Douglas B. Evans, Peter W. T. Pisters, Jeffrey E. Lee, Gauri R. Varadhachary, Donghui Li, Jean‐Nicolas Vauthey, Huamin Wang and Keping Xie. Their work appears in journals such as Journal of Clinical Oncology, Cancer, International Journal of Radiation Oncology*Biology*Physics, Annals of Surgical Oncology and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact